Substituted pyrrole derivatives and their use as HMG-CO inhibitors

A compound of the structure of Formula I,

• or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable tautomer, racemate, pure enantiomer, diastereoisomer or a lactone form or N-oxide thereof, wherein
• R1 is C1-C6 alkyl, C3-C6 cycloalkyl, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C1-C6 alkyl, cyano, and C1-C3 perfluoroalkyl);
• R2 is optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, and optionally substituted amino, wherein up to two amino substituents are independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, acetyl, and sulfonamide);
• R3 is optionally substituted C1-C6 alkyl or C3-C6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, C1-C3 alkoxy and protected hydroxyl);
• or
• R3 is —NR8R9, wherein R8 and R9 are optionally substituted C1-C6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C1-C3 alkoxy and protected hydroxyl);
• R4 is
• wherein R5 is hydrogen and R6 is aryl substituted with C1-C6 alkyl substituted with one or two substituents independently selected from hydroxyl and protected hydroxyl
• with the provisio that R2 is phenyl only when:
• R5 or R6 is phenyl substituted with hydroxyalkyl.